IL ‐25 Improves MAFLD by Suppressing the Notch Signalling in Hepatic Macrophages
Liver International · 2025
DOI: 10.1111/liv.70370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Xuelian Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Shenzhen Clinical Research Center for Digestive Disease, Shenzhen Hospital, Southern Medical Universit…. Hauptthemen laut MEDLINE: Macrophages, Interleukins, Receptor, Notch1, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Hepatic steatosis is characterised by hepatic lipid accumulation, inflammation and fibrosis, with macrophage polarisation playing a central role in disease progression. This study investigates the role of interleukin‐25 (IL‐25) in modulating macrophage polarisation and Notch signalling in a methionine‐choline‐deficient (MCD) diet‐induced metabolic dysfunction‐associated fatty liver disease (MAFLD) model.
Methods
C57BL/6 mice were fed a MCD diet to induce MAFLD. Human hepatocytes and primary hepatic macrophages were treated with palmitic acid and/or IL‐25. Methods included RT‐qPCR, ELISA, Western blot and immunofluorescence for gene/protein expression. ChIP and luciferase assays were used to analyse STAT3/Notch‐1 signalling.
Results
We found that IL‐25 expression was significantly downregulated in the livers of MCD‐fed mice and in palmitic acid‐treated hepatocytes. IL‐25 treatment promoted M2 macrophage polarisation, evidenced by increased expression of Arg1, Chi3l3 and anti‐inflammatory cytokines (IL‐10, TGF‐β), while suppressing pro‐inflammatory cytokines (TNF‐α, IL‐6). Mechanistically, IL‐25 inhibited the STAT3/Notch‐1 pathway and induced IL‐33, which negatively regulated the NF‐κB/Jagged‐1 axis, preventing M1 macrophage polarisation. Adoptive transfer of IL‐25‐induced M2a macrophages ameliorated hepatic steatosis and reduced ductular reaction in MCD‐fed mice.
Conclusions
These findings suggest a role for IL‐25 in modulating macrophage polarisation and inflammation in metabolic dysfunction‐associated fatty liver disease, supporting its further exploration as a potential therapeutic strategy for inflammatory liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Shenzhen Clinical Research Center for Digestive Disease, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
- Department of Pharmacy, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
- Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.
- Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
- Faculty of Forensic Medicine, Zhongshan School of Medicine, and Guangdong Province Translational Forensic Medicine Engineering Technology Research Center, Sun Yat-sen University, Guangzhou, China.
- Department of Gastroenterology and Hepatology, The First Afliated Hospital of Nanchang University, Nanchang, China.
Zitieren
APA
Zheng, X., Hu, D., Zhang, D., Chen, Y., Wei, J., Xie, B., & Wang, A. (2025). IL ‐25 Improves MAFLD by Suppressing the Notch Signalling in Hepatic Macrophages. Liver International. https://doi.org/10.1111/liv.70370
Vancouver
Zheng X, Hu D, Zhang D, Chen Y, Wei J, Xie B, et al. IL ‐25 Improves MAFLD by Suppressing the Notch Signalling in Hepatic Macrophages. Liver International. 2025. doi:10.1111/liv.70370
BibTeX
@article{Zheng2025,
author = {Zheng, Xuelian and Hu, Dandan and Zhang, Dongjing and Chen, Ye and Wei, Jianrui and Xie, Bo and Wang, Anjiang},
title = {IL ‐25 Improves MAFLD by Suppressing the Notch Signalling in Hepatic Macrophages},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70370}
}
EUVIMED